FDA has approved new indicationsfor the UroLift System (NeoTract),a treatment for benign prostatichyperplasia that involves placement,via a minimally invasive procedure, ofpermanent implants that relieve prostaticobstruction and open the urethra. 

UroLift is now approved for use inmen with an obstructive median lobeand men as young as 45 years. Previously,UroLift was contraindicated inpatients with an obstructive medianlobe and only approved for men aged50 years and older. FDA granted theexpanded indications based on theresults of the MedLift study.

From the April 01, 2018 Issue of Renal and Urology News

Topics:

Benign Prostatic Hyperplasia FDA